Visa to Move European Headquarters to London’s Canary Wharf 
GM Issues Recall for 2026 Chevrolet Silverado Trucks Over Missing Owner Manuals 
ExxonMobil to Shut Older Singapore Steam Cracker Amid Global Petrochemical Downturn 
U.S. Futures Steady as Rate-Cut Bets Rise on Soft Labor Data 
Gold Prices Edge Higher as Markets Await Key U.S. PCE Inflation Data 
Netflix’s Bid for Warner Bros Discovery Aims to Cut Streaming Costs and Reshape the Industry 
Asian Markets Stabilize as Wall Street Rebounds and Rate Concerns Ease 
Oil Prices Rise as Ukraine Targets Russian Energy Infrastructure 
Amazon Italy Pays €180M in Compensation as Delivery Staff Probe Ends 
Australia Moves Forward With Teen Social Media Ban as Platforms Begin Lockouts 
Gold Prices Steady as Markets Await Key U.S. Data and Expected Fed Rate Cut 
Michael Dell Pledges $6.25 Billion to Boost Children’s Investment Accounts Under Trump Initiative 
Rio Tinto Raises 2025 Copper Output Outlook as Oyu Tolgoi Expansion Accelerates 
Momenta Quietly Moves Toward Hong Kong IPO Amid Rising China-U.S. Tensions 
Microchip Technology Boosts Q3 Outlook on Strong Bookings Momentum 
Proxy Advisors Urge Vote Against ANZ’s Executive Pay Report Amid Scandal Fallout 
Pfizer inc., an American pharmaceutical and biotechnology firm headquartered in Manhattan, New York City, has agreed to buy Global Blood Therapeutics biotech company for $5.4 billion. The drugmaker will be paying $68.50 a share for the acquisition.
According to Reuters, Pfizer will purchase the blood disorder medicine producer as it would like to bolster its drug lineup to counter or fight a possible slowdown in the demand for COVID medicines and other products since the cases are starting to fall.
Pfizer was one of the drugmakers that earned the most at the height of the COVID-19 pandemic since it supplied the vaccines around the world. With most people worldwide now fully vaccinated, the company is now looking for acquisitions that will bring in profits annually
Pfizer confirmed on Monday, Aug. 8, that it will be paying $68.50 per share to buy Global Blood Therapeutics. This amount is equivalent to a premium of around 7.3% to the stock's closing price last Friday.
Following the announcement of the deal with Pfizer, the shares of Global Blood reportedly soared by 4.5%. The company is known for its blood disorder drug called Oxbryta, which was first approved in 2019.
It is used for the treatment of sickle cell disease in patients who are 12 years old or older. In December 2021, it was also approved for the treatment of younger patients who are suffering from the said disease.
“Sickle cell disease is the most common inherited blood disorder, and it disproportionately affects people of African descent. We are excited to welcome GBT colleagues into Pfizer and to work together to transform the lives of patients, as we have long sought to address the needs of this underserved community,” Pfizer’s chairman and chief executive officer, Albert Bourla, said in a press release.
He added, “The deep market knowledge and scientific and clinical capabilities we have built over three decades in rare hematology will enable us to accelerate innovation for the sickle cell disease community and bring these treatments to patients as quickly as possible.”
